The Lung Inflammatory Disease Program of Excellence in Glycosciences (LID-PEG) has Projects and Cores at three institutions and a breadth of capabilities ranging from chemistry to preclinical therapeutic models. With this diversity, communications will be a key to LID-PEG progress and success. A major role in effective communication will be provided by Core A, the Administrative Core. Core A will take responsibility for inter-program communications both through web-based video conferencing and face-to-face meetings. The Core will coordinate and oversee the regular video-conference meetings of the Executive Committee, organize the annual Program Group Meeting (which will rotate among the three sites), organize meetings of the LID-PEG with its Internal and External advisory boards and support LID-PEG participation in the annual Investigator's meeting in Bethesda. In addition to travel planning and reimbursement for LID-PEG meeting participants. Core A will coordinate communications with NHLBI and the Administrative Center, manage budgets and fulfill NIH reporting requirements.

Public Health Relevance

This Program brings together scientists from across the country to combine diverse expertise in glycosciences with the goal of discovering new therapies for asthma, COPD and other lung and cardiovascular inflammatory diseases. Effective communication is essential to this goal, and Core A will take the lead in ensuring efficient communications among LID-PEG members.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL107151-03
Application #
8477259
Study Section
Special Emphasis Panel (ZHL1-CSR-H)
Project Start
Project End
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
3
Fiscal Year
2013
Total Cost
$145,858
Indirect Cost
$57,398
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Kumagai, Tadahiro; Kiwamoto, Takumi; Brummet, Mary E et al. (2018) Airway glycomic and allergic inflammatory consequences resulting from keratan sulfate galactose 6-O-sulfotransferase (CHST1) deficiency. Glycobiology 28:406-417
Wei, Yadong; Chhiba, Krishan D; Zhang, Fengrui et al. (2018) Mast Cell-Specific Expression of Human Siglec-8 in Conditional Knock-in Mice. Int J Mol Sci 20:
Li, Tao; Hu, Rong; Chen, Zi et al. (2018) Fine particulate matter (PM2.5): The culprit for chronic lung diseasesĀ in China. Chronic Dis Transl Med 4:176-186
Robida, Piper A; Puzzovio, Pier Giorgio; Pahima, Hadas et al. (2018) Human eosinophils and mast cells: Birds of a feather flock together. Immunol Rev 282:151-167
O'Sullivan, Jeremy A; Carroll, Daniela J; Cao, Yun et al. (2018) Leveraging Siglec-8 endocytic mechanisms to kill human eosinophils and malignant mast cells. J Allergy Clin Immunol 141:1774-1785.e7
O'Sullivan, Jeremy A; Wei, Yadong; Carroll, Daniela J et al. (2018) Frontline Science: Characterization of a novel mouse strain expressing human Siglec-8 only on eosinophils. J Leukoc Biol 104:11-19
Edgar, Landon J; Kawasaki, Norihito; Nycholat, Corwin M et al. (2018) Targeted Delivery of Antigen to Activated CD169+ Macrophages Induces Bias for Expansion of CD8+ T Cells. Cell Chem Biol :
Khoury, Paneez; Bochner, Bruce S (2018) Consultation for Elevated Blood Eosinophils: Clinical Presentations, High Value Diagnostic Tests, and Treatment Options. J Allergy Clin Immunol Pract 6:1446-1453
Chen, Zi; Bai, Fang-Fang; Han, Lu et al. (2018) Targeting Neutrophils in Severe Asthma via Siglec-9. Int Arch Allergy Immunol 175:5-15
O'Sullivan, Jeremy A; Bochner, Bruce S (2018) Eosinophils and eosinophil-associated diseases: An update. J Allergy Clin Immunol 141:505-517

Showing the most recent 10 out of 78 publications